+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pharmacotherapy of cardiac arrhythmias in women--what do we know, do we have a choice?

Pharmacotherapy of cardiac arrhythmias in women--what do we know, do we have a choice?

Przeglad Lekarski 71(3): 155-159

The paper presents basic epidemiological, electrophysiological and therapeutical differences of cardiac arrhythmias depended on gender. Inadequate sinus tachycardia, orthostatic tachycardia syndrome and atrioventricular nodal reentrant tachycardia are more common in women as well as prolongation of QT interval and proarrhythmic phenomenon (especially torsade de pointes). Atrial fibrillation, although significantly less common in women, is more onerous, therapeutic aims are worse to achieve and outcomes are less favourable than in men. European guidelines do not recommend different pharmacological treatement of supraventricular and ventricular arrhythmias in relation to gender. Older antyarrhythmic drugs (beta-adrenolytics, amiodarone, sotalol) and as well as newer ones (dronedarone, ivabradine, vernakalant and ranolazine) seem to have the same influence on arrthythmias both in men and women, althouth their long-term safety may be different and depend on influence on QT interval. The paper presents the state of the art of antiarrhythmic drugs that might be prefered among woman in different clinical situations.

(PDF emailed within 1 workday: $29.90)

Accession: 054963486

Download citation: RISBibTeXText

PMID: 25154213

Related references

Basis of pharmacotherapy of cardiac arrhythmias. Modern Concepts of Cardiovascular Disease 31: 739-744, 1962

How much do we understand about pharmacotherapy of cardiac arrhythmias?. Lijecnicki Vjesnik 115(5-6): 156-159, 1993

Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). Circulation Journal 77(1): 249-274, 2013

Pharmacotherapy of cardiac arrhythmias in acute myocardial infarction. Folia Medica Neerlandica 14(5): 225-236, 1971

Neuropsychiatric sequelae of pharmacotherapy of cardiac arrhythmias and hypertension. Journal of Clinical Psychopharmacology 1(6): 394-398, 1981

Pharmacotherapy of cardiac arrhythmias--basic science for clinicians. Pacing and Clinical Electrophysiology 32(11): 1454-1465, 2010

Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation. Journal of Pharmacological and Toxicological Methods 57(1): 1-8, 2007

Possibilities and trends of pharmacotherapy of cardiac arrhythmias in childhood and adolescence. 1: General principles, clinical aspects and indications. Zeitschrift für Arztliche Fortbildung 82(5): 205-208, 1988

Resuscitation great. Paul M. Zoll, M.D.-- the father of "modern" electrotherapy and innovator of pharmacotherapy for life-threatening cardiac arrhythmias. Resuscitation 73(2): 178-185, 2007

Possibilities and trends of pharmacotherapy of cardiac arrhythmias in childhood and adolescence. 3: Determinative criteria, therapeutic concept and selection of drugs. Zeitschrift für Arztliche Fortbildung 82(7): 305-309, 1988

Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. Journal of the American Academy of Child and Adolescent Psychiatry 34(9): 1239-45; Discussion 1245-8, 1995

Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese. Journal of Human Nutrition and Dietetics 15(4): 287-295, 2002

Cardiac arrhythmias and sudden cardiac death in women. Zeitschrift für Kardiologie 93(6): 427-438, 2004

Disclosing Genetic Information to Family Members About Inherited Cardiac Arrhythmias: An Obligation or a Choice?. Journal of Genetic Counseling 24(4): 608-615, 2016

Cardiac arrhythmias in women. Revue Medicale de Liege 54(4): 251-254, 1999